# Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer

> **NCT01347866** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 105 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** PF-05212384
- **DRUG:** PD-0325901
- **DRUG:** PF-05212384
- **DRUG:** irinotecan

## Key facts

- **NCT ID:** NCT01347866
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-10
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 105 (ACTUAL)
- **Why stopped:** Refer to Detailed Description for documentaion of Termination Statement.
- **Last updated:** 2018-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01347866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01347866, "Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01347866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*